Cargando…

Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy

INTRODUCTION: Few data are available on the risk of SAEs in corticosteroid users in IgAN populations. We describe the prevalence and risk factors of corticosteroid-related SAEs in a Chinese cohort. METHODS: A total of 1034 IgAN patients were followed up in our renal center from 2003 to 2014. Prevale...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Qingqing, Xie, Xinfang, Wang, Jinwei, Shi, Sufang, Liu, Lijun, Chen, Yuqing, Lv, Jicheng, Zhang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678641/
https://www.ncbi.nlm.nih.gov/pubmed/29142978
http://dx.doi.org/10.1016/j.ekir.2017.02.003
_version_ 1783277479661666304
author Cai, Qingqing
Xie, Xinfang
Wang, Jinwei
Shi, Sufang
Liu, Lijun
Chen, Yuqing
Lv, Jicheng
Zhang, Hong
author_facet Cai, Qingqing
Xie, Xinfang
Wang, Jinwei
Shi, Sufang
Liu, Lijun
Chen, Yuqing
Lv, Jicheng
Zhang, Hong
author_sort Cai, Qingqing
collection PubMed
description INTRODUCTION: Few data are available on the risk of SAEs in corticosteroid users in IgAN populations. We describe the prevalence and risk factors of corticosteroid-related SAEs in a Chinese cohort. METHODS: A total of 1034 IgAN patients were followed up in our renal center from 2003 to 2014. Prevalence of corticosteroid use and corticosteroid-related SAEs were noted. Logistic regression was used to search for risk factors of SAEs in corticosteroid users. RESULTS: Of the 369 patients with steroids therapy, 46 patients (12.5%) with 58 events suffered SAEs, whereas only 18 patients (2.7%) without corticosteroids suffered SAEs (OR: 5.45; 95% CI: 3.07–9.68; P < 0.001). SAEs included diabetes mellitus (n = 19, 5.1%), severe or fatal infection (n = 18, 4.9%), osteonecrosis of the femoral head or bone fracture (n = 6, 1.6%), cardiocerebral vascular disease (n = 4, 1.1%), cataract (n = 3, 0.8%), and gastrointestinal hemorrhage (n = 1, 0.3%). Multivariable logistic regression analysis revealed that advanced age (OR: 1.05; 95% CI: 1.02–1.07; P < 0.001) and hypertension (OR: 1.04; 95% CI: 1.01–1.06; P = 0.009) were risk factors for corticosteroid-related SAEs. Impaired kidney function (estimated GFR: OR: O.98; 95% CI: 0.96–0.99; P = 0.036) was a risk factor for severe infection. Accumulated dosages of corticosteroids were not identified as a risk factor of SAEs (OR: 1.09; 95% CI: 0.91–1.30; P = 0.365). DISCUSSION: Corticosteroid use is associated with a high risk of SAEs in IgAN patients, especially those who are older, have hypertension, or impaired renal function. Current guidelines on corticosteroid regimens in IgAN should be reviewed with regard to safety.
format Online
Article
Text
id pubmed-5678641
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-56786412017-11-15 Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy Cai, Qingqing Xie, Xinfang Wang, Jinwei Shi, Sufang Liu, Lijun Chen, Yuqing Lv, Jicheng Zhang, Hong Kidney Int Rep Clinical Research INTRODUCTION: Few data are available on the risk of SAEs in corticosteroid users in IgAN populations. We describe the prevalence and risk factors of corticosteroid-related SAEs in a Chinese cohort. METHODS: A total of 1034 IgAN patients were followed up in our renal center from 2003 to 2014. Prevalence of corticosteroid use and corticosteroid-related SAEs were noted. Logistic regression was used to search for risk factors of SAEs in corticosteroid users. RESULTS: Of the 369 patients with steroids therapy, 46 patients (12.5%) with 58 events suffered SAEs, whereas only 18 patients (2.7%) without corticosteroids suffered SAEs (OR: 5.45; 95% CI: 3.07–9.68; P < 0.001). SAEs included diabetes mellitus (n = 19, 5.1%), severe or fatal infection (n = 18, 4.9%), osteonecrosis of the femoral head or bone fracture (n = 6, 1.6%), cardiocerebral vascular disease (n = 4, 1.1%), cataract (n = 3, 0.8%), and gastrointestinal hemorrhage (n = 1, 0.3%). Multivariable logistic regression analysis revealed that advanced age (OR: 1.05; 95% CI: 1.02–1.07; P < 0.001) and hypertension (OR: 1.04; 95% CI: 1.01–1.06; P = 0.009) were risk factors for corticosteroid-related SAEs. Impaired kidney function (estimated GFR: OR: O.98; 95% CI: 0.96–0.99; P = 0.036) was a risk factor for severe infection. Accumulated dosages of corticosteroids were not identified as a risk factor of SAEs (OR: 1.09; 95% CI: 0.91–1.30; P = 0.365). DISCUSSION: Corticosteroid use is associated with a high risk of SAEs in IgAN patients, especially those who are older, have hypertension, or impaired renal function. Current guidelines on corticosteroid regimens in IgAN should be reviewed with regard to safety. Elsevier 2017-02-09 /pmc/articles/PMC5678641/ /pubmed/29142978 http://dx.doi.org/10.1016/j.ekir.2017.02.003 Text en © 2017 International Society of Nephrology. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical Research
Cai, Qingqing
Xie, Xinfang
Wang, Jinwei
Shi, Sufang
Liu, Lijun
Chen, Yuqing
Lv, Jicheng
Zhang, Hong
Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy
title Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy
title_full Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy
title_fullStr Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy
title_full_unstemmed Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy
title_short Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy
title_sort severe adverse effects associated with corticosteroid treatment in patients with iga nephropathy
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678641/
https://www.ncbi.nlm.nih.gov/pubmed/29142978
http://dx.doi.org/10.1016/j.ekir.2017.02.003
work_keys_str_mv AT caiqingqing severeadverseeffectsassociatedwithcorticosteroidtreatmentinpatientswithiganephropathy
AT xiexinfang severeadverseeffectsassociatedwithcorticosteroidtreatmentinpatientswithiganephropathy
AT wangjinwei severeadverseeffectsassociatedwithcorticosteroidtreatmentinpatientswithiganephropathy
AT shisufang severeadverseeffectsassociatedwithcorticosteroidtreatmentinpatientswithiganephropathy
AT liulijun severeadverseeffectsassociatedwithcorticosteroidtreatmentinpatientswithiganephropathy
AT chenyuqing severeadverseeffectsassociatedwithcorticosteroidtreatmentinpatientswithiganephropathy
AT lvjicheng severeadverseeffectsassociatedwithcorticosteroidtreatmentinpatientswithiganephropathy
AT zhanghong severeadverseeffectsassociatedwithcorticosteroidtreatmentinpatientswithiganephropathy